<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Institution Vote</th>
</tr>
</thead>
</table>
| **BRCA-1**                | **External request**  
Submission request from Myriad Genetic Laboratories to Modify the BRCA1/2 testing criteria on page BRCA-1 to include the following:  
1. Expanded criteria for patients with a personal history of pancreatic cancer  
a. Replace bullet points 6 and 7 with “Personal history of pancreatic cancer at any age.”  
For the BRCA-1 page, the panel consensus was not to replace bullet points 6 and 7 with “Personal history of pancreatic cancer at any age” until more evidence is available.  
- See Submission for references.                                                                                                                                                                                                                                                                                                                                 | YES  | NO  | ABSTAIN | ABSENT |
|                           | 0                 | 20                | 0           | 8                  |
| **External request**      | Submission request from Myriad Genetic Laboratories to provide specific testing criteria, as well as management recommendations, for PALB2 analogous to the testing criteria and recommendations provided for BRCA1/2, PHTS, LFS, and the other genes/ syndromes addressed in the guidelines.  
The panel discussion and consensus was not to provide specific testing criteria, as well as management recommendations, for PALB2 analogous to the testing criteria and recommendations provided for BRCA1/2, PHTS, LFS, and the other genes/ syndromes addressed in the guidelines.  
- See Submission for references.                                                                                                                                                                                                                                                                                                                                 | YES  | NO  | ABSTAIN | ABSENT |
|                           | 0                 | 20                | 0           | 8                  |
| **External request**      | Submission request from Myriad Genetic Laboratories to delete bullet point 7 on GENE-1 (regarding moderate penetrance genes) and modify bullet point 2 as follows:  
The majority of patients meeting assessment and testing criteria for inherited breast and/or ovarian cancer risk have personal and/or family histories that can be explained by  
The panel discussion and consensus was not to modify GENE-1 as requested.  
- See Submission for references.                                                                                                                                                                                                                                                                                                                                 | YES  | NO  | ABSTAIN | ABSENT |
|                           | 0                 | 20                | 0           | 8                  |
multiple genes or syndromes, and are therefore most appropriately tested with a multi-gene panel. A small subset of patients with a personal or family history narrowly suggestive of a single syndrome with highly distinctive features (e.g., Peutz-Jeghers Syndrome or Neurofibromatosis I) may be most appropriately managed by genetic testing for that specific syndrome.